IMIDomics
Signal active
Organization
Contact Information
Overview
IMIDomics is a unique company tackling Immune-Mediated Inflammatory Diseases (IMIDs). As an innovative leader in discovery and application of biomarkers and new targets to monitor and cure IMIDs, we create value through the combination of the world's largest IMID biobank, extensive relevant clinical expertise, high-throughput genomic and genetic analysis, and intellectual property. IMIDomics is located at Vall d'Hebron Hospital in Barcelona, Spain and on the HudsonAlpha Institute campus in Huntsville, Alabama.
About
Industries
Biotechnology, Health Care
Founded
2015
Employees
11-50
Headquarters locations
Europe
Social
N/A
Profile Resume
IMIDomics headquartered in Europe, operates in the Biotechnology, Health Care sector. The company focuses on Biotechnology and has secured $396.0M in funding across 24 round(s). With a team of 11-50 employees, IMIDomics is actively contributing to advancements in Biotechnology. Their latest funding round, Corporate Round - IMIDomics, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
3
Investors
1
Lead Investors
0
Total Funding Amount
$16.5M
Details
1
IMIDomics has raised a total of $16.5M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2021 | Early Stage Venture | 16.5M |
Investors
IMIDomics is funded by 10 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| DNS Capital | - | FUNDING ROUND - DNS Capital | 16.5M |
| Evotec | - | FUNDING ROUND - Evotec | undefined |
| IMIDomics | - | FUNDING ROUND - IMIDomics | undefined |
| Union Chimique Belge | - | FUNDING ROUND - Union Chimique Belge | undefined |
Recent Activity
There is no recent news or activity for this profile.